Abstract Our goal was to study the prevalence of systemic sclerosis (SSc) subtypes, autoantibody profile, and pulmonary fibrosis in a large group of Han Chinese. Chinese SSc patients (n=419) were recruited from a multicenter study including hospitals and outpatient clinics in China. All patients met the American College of Rheumatology classification criteria for SSc. Anti-topoisomerase (ATA), anti-centromere (ACA), anti-RNA polymerase III (anti-RNAP3), and anti-U1-ribonucleoprotein (anti-U1RNP) were detected utilizing commercially available kits. The clinical and autoantibody information in Chinese patients was compared to that in the US Caucasian patients (n=834), recruited from the Genetics versus Environment in Scleroderma Outcome Study and Scleroderma Family Registry. Chi-square test was utilized for the abovementioned comparisons. Chinese patients showed 40.3 % limited (lcSSc) and 59.7 % diffuse (dcSSc) forms of SSc. ATA was found in 59.9 %, ACA in 13.4 %, anti-RNAP3 in 1.3 %, and anti-U1RNP in 18 % of Chinese SSc patients. Compared to US patients (65.1 % lcSSc, 34.9 % dcSSc, ATA in 18.7 %, ACA in 32.4 %, anti-RNAP3 in 17.4 %, and anti-U1RNP in 2.8 %), Chinese SSc patients are significantly higher in dcSSc and the frequencies of ATA and anti-U1RNP, but lower in ACA and anti-RNAP3. In addition, pulmonary fibrosis was observed in 78 % Chinese SSc patients and was strongly associated with the presence of ATA. The present study represents the first report of SSc features in a large group of Chinese patients. Clinical subtypes and the frequencies of SSc-related autoantibodies in Chinese
Introduction
Systemic sclerosis (SSc) or scleroderma is a rare and complex autoimmune disease. It is clinically classified into two subsets: limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) SSc. The latter subset is characterized by more rapid progression of skin and visceral involvement as well as poorer prognosis [1] . SSc also can be subgrouped by autoantibody subsets. The most common of these autoantibodies are directed against DNA topoisomerase I (ATA), centromeric proteins (ACA), and RNA polymerases III (anti-RNAP3), as well as other less commonly occurring autoantibodies including U1-ribonucleoprotein (anti-U1RNP) [1] . Individual SSc patients rarely have more than one of these autoantibodies, and each autoantibody subset is associated with certain disease features [2] . Previously, several studies suggested that the prevalence of SSc subsets varies in different ethnic groups. For instance, the patients of Choctaw Native American and African American descent are more likely to develop dcSSc compared to the patients of European descent [3, 4] . Furthermore, Choctaw Native Americans, African Americans, Koreans, and Thais have relatively higher frequencies of ATA [3] [4] [5] [6] . Although Han Chinese is a large population, only one report on Chinese SSc with a small sample size was previously reported [7] . Recently, we established a multicenter SSc consortium in China under the International Network of Scleroderma Clinical Care and Research (http://www.inscar-global.org). The goal of the present study is to investigate the prevalence of SSc disease subtypes, autoantibody profile, and organ involvement in a large group of Han Chinese patients with SSc.
Materials and methods

Patient enrollment
Chinese patients were recruited from a multicenter study including hospitals and outpatient clinics in Shanghai, Hebei Province, Sichuan Province, and Hunan Province in China. Patients either met the American College of Rheumatology classification criteria for SSc (96.1 % of Chinese patients) [8] or had at least three out of five CREST features (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) with sclerodactyly being mandatory (3.9 %) [9] . Mean duration of the disease was 7.3 years ranging from 1 to 32 years (from the first nonRaynaud's phenomenon symptom). Diagnosis of pulmonary fibrosis was confirmed with either chest X-ray (41.9 %) or thorax CT (58.1 %) in different hospitals. The US Caucasian patients (n=834) were recruited from the Genetics versus Environment in Scleroderma Outcome Study and Scleroderma Family Registry [10] . The ethical approvals of the studies were obtained from each institutional review board.
Autoantibody tests
Patient's sera were tested for antinuclear antibodies (ANA) by indirect immunofluorescence using HEp-2 cells as antigen substrate (Antibodies, Davis, CA, USA). ATA and anti-U1RNP were detected by passive immunodiffusion against calf thymus extracts (INOVA Diagnostics). ACA was determined by indirect immunofluorescence using HEp-2 cells. Anti-RNAP3 was detected utilizing commercially available kits (NBL, Nagoya, Japan).
Statistical analysis
Chi-square test was utilized for the abovementioned comparisons. The p values less than 0.05 were considered statistically significant. The statistical program Epi Info™ 3.5.4 was used in the analysis. All Chinese patients were examined for ATA and ACA. In addition, 303 Chinese consecutive patients were assayed for anti-RNAP3 and 311 for anti-U1RNP. ATA was found in 251 (59.9 %), ACA in 56 (13.4 %), anti-RNAP3 in 4 (1.3 %), and anti-U1RNP in 56 (18 %) patients, while 90.7 % of patients were ANA positive.
The comparison of Chinese SSc patients to 834 SSc patients of self-reported European decent (US Caucasian) is shown in Table 1 . ATA, ACA, anti-RNAP3, and anti-U1RNP were observed in 156 (18.7 %), 270 (32.4 %), 145 (17.4 %), and 23 (2.8 %) US Caucasian patients, respectively. The frequencies of ATA and anti-U1RNP were significantly higher among Chinese patients, while the ACA and anti-RNAP3 were more prevalent among US Caucasian patients. Chinese patients also had a higher proportion of the dcSSc subtype than US Caucasian patients (60 versus 35 %).
The associations of these autoantibodies with clinical subtypes of Chinese SSc are shown in Table 2 . Among 251 ATA-positive SSc patients, there were 161 with dcSSc (64.1 %) and 90 with lcSSc (35.9 %) compared with 168 ATA-negative patients of whom 89 had dcSSc (53 %) and 79 had lcSSc (47 %). ATA was associated with dcSSc in Chinese patients (p=0.029, odds ratio (OR)=1.59). SSc patients with ACA, anti-RNAP3, and anti-U1RNP did not show association with either dcSSc or lcSSc (p>0.05).
There were 328 Chinese patients examined with chest Xray and/or thorax CT for diagnosis of pulmonary fibrosis. The associations of pulmonary fibrosis with the presence of specific autoantibodies in Chinese patients are shown in Table 3 . Pulmonary fibrosis was observed in 161 of 187 ATA-positive and in 95 of 141 ATA-negative patients, indicating a strong association of ATA with pulmonary fibrosis (p=8.84×10 
Discussion
The present study represents the largest report on the SScrelated autoantibodies and clinical subtypes in patients of Han Chinese decent. Herein, we demonstrated for the first time that Chinese SSc patients appeared similar to patients of European descent in gender distribution and ANA positivity, but differ in the proportion of clinical subsets and frequencies of SSc-related autoantibodies. A higher proportion of dcSSc and pulmonary fibrosis was observed in the Chinese cohort compared to the US cohort. This observation is similar to that in SSc patients of Choctaw Native American and African American descent [3, 4] .
The differences in frequency of SSc-related autoantibodies between Han Chinese and US Caucasian patients were significant in all four autoantibodies examined. A higher frequency of ATA (59.9 %) and anti-U1RNP (18 %), but a lower occurrence of ACA (13.4 %) and anti-RNAP3 (1.3 %), was observed in Chinese SSc patients. It is noteworthy that a previous report of 36 SSc patients of Chinese descent showed that ATA and anti-RNP antibodies were present in 48.4 and 17.2 %, respectively [6] , paralleling the autoantibody frequencies observed in the present study. In addition, the frequencies of ATA and ACA in Chinese SSc are very close to a previous report in Korean SSc patients (62.2 % ATA and 12.03 % ACA) [4] . Moreover, a high frequency of ATA (76 %) and a low frequency of ACA (2 %) also were reported in SSc patients of Thai decent [5] . These data indicate a high frequency of ATA and a low frequency of ACA positivity among Asian SSc patients.
Similar to the findings in other ethnic populations [2, 9, 10] , the presence of ATA in Chinese SSc patients was strongly associated with dcSSc and pulmonary fibrosis, while ACA was correlated with less pulmonary involvement (Table 3) . On the other hand, in addition to a higher proportion of dcSSc in ATA-positive patients (64.1 %), ACApositive Chinese patients also have a relatively high occurrence of dcSSc (55.4 %), which appeared unique to this Chinese cohort.
A markedly low frequency of anti-RANP3 (1.3 %) among Chinese SSc patients is a novel finding. There were also reports of low prevalence of anti-RANP3 in Japanese and European populations including French and Italian (4, 9.1, and 8 %, respectively) [11] [12] [13] . Considering that RNAP3 is strongly associated with scleroderma renal crisis [14] , we expect that Chinese SSc patients have a low prevalence of this disease manifestation.
The frequency of anti-U1RNP observed in the Chinese cohort (18 %) is significantly higher than that in the US cohort (2.8 %). Neither clinical subtypes nor pulmonary fibrosis was associated with the presence of this antibody in any of the two cohorts. Interestingly, a higher frequency of anti-U1RNP (30 %) also was reported in SSc patients of African American population [15] . We do not believe that the observed higher frequency of patients with dcSSc and ATA among Chinese patients is secondary to referral bias because patients were recruited from a wide geographic area that included inpatient and outpatient clinics.
In summary, the present study represents the first report of clinical subtypes and autoantibodies of SSc in a large sample of Chinese patients. We demonstrate that the frequencies of SSc-related autoantibodies and clinical subtypes in Chinese patients with SSc are significantly different from US Caucasian SSc patients in the USA. The autoantibody profile among Chinese patients with SSc is similar to that among other Asian populations. These findings suggest that SSc patients in various geographic areas differ in their serological and clinical manifestations.
